-+ 0.00%
-+ 0.00%
-+ 0.00%
Amylyx Publishes Presentation on Avexitide Phase 3 LUCIDITY Trial Results
Share
Listen to the news
Amylyx Publishes Presentation on Avexitide Phase 3 LUCIDITY Trial Results
  • Amylyx Pharmaceuticals published its ObesityWeek presentation detailing pivotal Phase 3 LUCIDITY results for avexitide in post-bariatric hypoglycemia.
  • Avexitide met the primary endpoint, reducing the composite rate of level 2/3 hypoglycemic events by 55% versus placebo; p=0.0000034.
  • Model-adjusted weekly event rates were 0.55 with avexitide versus 1.24 with placebo during the 16-week double-blind period.
  • The trial randomized 78 participants; primary endpoint results were consistent across prespecified sensitivity analyses and evaluated subgroups.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amylyx Pharmaceuticals Inc. published the original content used to generate this news brief on November 15, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending